Beckley Psytech

Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics' Effects On The Brain
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage
Phase 2 Trial For This Psychedelic, Potential Treatment For Severe Depression
Beyond Magic Mushrooms: Positive Clinical Trial For Treatment-Resistant Depression & Alcoholism

Beckley Psytech Recent News

Psyched: UK Streamlines MDMA Therapy, FDA OKs MindMed's First LSD Trial In 40 years, Atai Launches Subsidiary
The Week In Psychedelics
Beckley Psytech Begins Training Therapists For Phase 2 Trial With Toad Venom, 5-MeO-DMT
Beckley Psytech, a private company in the psychedelics space, announced that it has begun training psychotherapists for a Phase 2 clinical trial with 5-MeO-DMT, a strong and fast-acting psychedeli
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Beckley Psytech Closes $80 Million Series B
Beckley Psytech Reaches $100M Financing To Study 5-MeO-DMT, Psilocybin And Other Psychedelics
Beckley Psytech, an Oxford-based psychedelics research company, announced the closing of a £58 million ($80 million) Series B raise, which will be used to further finance the company’s psilocybin and
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In just a couple of years, psychedelics took the world of investing by storm.
Psychedelic Compound 5-MeO-DMT Could Make Therapy Short And Effective: Beckley Psytech Is 'All In'
5-MeO-DMT is a potent and fast-acting psychedelic, which is naturally produced by the Sonoran Desert toad as well as some species of plants. Its short duration –from 20 minutes to one hour– is giving hope to researchers and executives in the psychedelics space who are seeking an alternative to the otherwise lengthy treatment sessions of psilocybin and MDMA.
Psyched: The First Psychedelics ETF, Beckley Raises $19M, 3 Companies Go Public
The Psychedelics Sector Might Soon Get Its First ETF Financial services company Horizons ETFs Management filed documents with the Ontario Securities Commission for a psychedelics ETF, which is expected to go live on Jan. 15.
'Psyched': Atai Buys Kures, Beckley Psytech Raises $3.7M, Mydecine Acquires NeuroPharma
PSYCHED is now weekly! As the psychedelics industry grows, so does the need for news. For this reason, our column covering the most important developments in medicinal psychedelics is now a weekly feature.